It was proven that concomitant mutations were ubiquitous in patients who harbored with EGFR‐mutant advanced NSCLC and that NSCLC may no longer be treated as a single oncogene‐driven disease.37, 38. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.